GLP-1 receptor agonists are a revolutionary treatment for obesity and investigations into other uses of these agents are ongoing. Epidemiologic data suggest that prostate cancer risk may decrease following GLP-1 receptor agonist initiation.
To better define the potential role of GLP-1 receptor agonist use among men with prostate cancer, we will define changes that occur in men with prostate cancer following lifestyle intervention; illuminate the current relationship between these interventions and prostate cancer risk; and explore the potential mechanism of action on tumor biology, providing rationale for evaluating its effects on prostate cancer in a planned clinical trial.
Urology. 2025 May 08 [Epub ahead of print]
Andrew Fang, Daniel E Frigo, Andrew Hahn, Zayd Razouki, Jessica Hwang, Efstratios Koutroumpakis, Tarek Lawen, Matthew Smith, Jill Hamilton-Reeves, John DiGiovanni, Noel Higgason, Rebekka S Garcia, Brian F Chapin, Curtis Pettaway, Lisly Chery, Patricia Troncoso, Christopher Logothetis, Carrie R Daniel, Peng Wei, Justin R Gregg
The University of Texas MD Anderson Cancer Center, Houston, TX USA., The University of Kansas Medical Center, Kansas City, KS USA., The University of Texas College of Pharmacy, Austin, TX USA., The University of Texas MD Anderson Cancer Center, Houston, TX USA. Electronic address: .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/40348027